Mawer Investment Management Ltd. Sells 1,465 Shares of Becton, Dickinson and Company $BDX

Mawer Investment Management Ltd. lowered its position in Becton, Dickinson and Company (NYSE:BDX) by 0.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 442,162 shares of the medical instruments supplier’s stock after selling 1,465 shares during the period. Mawer Investment Management Ltd. owned 0.15% of Becton, Dickinson and Company worth $76,162,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in BDX. Vanguard Group Inc. boosted its stake in Becton, Dickinson and Company by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock worth $6,414,322,000 after purchasing an additional 1,259,750 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in Becton, Dickinson and Company by 3.7% in the first quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier’s stock worth $2,880,510,000 after buying an additional 448,644 shares during the last quarter. First Eagle Investment Management LLC lifted its stake in shares of Becton, Dickinson and Company by 59.2% in the second quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier’s stock worth $1,513,421,000 after buying an additional 3,268,478 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Becton, Dickinson and Company by 10.8% during the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock valued at $1,567,654,000 after buying an additional 667,957 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Becton, Dickinson and Company by 7.6% during the first quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier’s stock valued at $1,012,649,000 after acquiring an additional 312,124 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Bertram L. Scott sold 217 shares of the business’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the sale, the director directly owned 35,816 shares in the company, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director owned 22,226 shares of the company’s stock, valued at $4,167,375. This represents a 3.96% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 1,249 shares of company stock worth $231,358 over the last ninety days. Insiders own 0.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on BDX shares. Stifel Nicolaus lowered their price objective on Becton, Dickinson and Company from $224.00 to $210.00 in a research report on Friday. Wells Fargo & Company upped their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a report on Friday, August 8th. Royal Bank Of Canada reduced their price objective on Becton, Dickinson and Company from $211.00 to $202.00 and set a “sector perform” rating for the company in a report on Friday. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Finally, Piper Sandler reduced their price target on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday. Three research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $203.27.

Becton, Dickinson and Company Stock Up 2.1%

Shares of BDX stock opened at $181.62 on Tuesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. Becton, Dickinson and Company has a one year low of $162.29 and a one year high of $251.99. The company’s fifty day moving average price is $186.54 and its 200-day moving average price is $181.99. The company has a market capitalization of $52.06 billion, a price-to-earnings ratio of 32.67, a PEG ratio of 1.42 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business had revenue of $5.32 billion for the quarter. Sell-side analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th will be issued a dividend of $1.05 per share. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date of this dividend is Monday, December 8th. This represents a $4.20 annualized dividend and a dividend yield of 2.3%. Becton, Dickinson and Company’s payout ratio is currently 71.36%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.